KKR Makes $475M Bet in San Diego's Life Science Market
KKR invested $475M in Alexandria Real Estate Equities' 2M sq ft San Diego life science campus, taking a 49% stake. The joint venture will support leasing and development. Alexandria's CEO called it a step to optimize capital. Tenants include Bristol Myers Squibb and Eli Lilly. KKR has invested $20B in life sciences since 2004.
How this was made

The 30-second read
Why it matters
The deal provides Alexandria with capital to upgrade and lease space, while giving KKR exposure to a high‑growth sector.
Market read
A major private‑equity investment in a biotech REIT could influence sector sentiment and related stocks.
What to watch
Potential regulatory or zoning changes and the long‑term lease concentration with a few large biotech tenants.
Background
KKR expands its life‑science portfolio with a sizable stake in Alexandria's Campus Point, a premier biotech campus in San Diego.
Ticker impact
Alexandria Real Estate Equities received a $475 million cash investment from KKR for a 49% stake in its Campus Point Megacampus.
likely upside as market prices in the new capital and partnership
Large cash investment and strategic partnership improve balance sheet and growth prospects.
KKR invested $475 million to acquire a 49% minority stake in Alexandria's Campus Point property.
potential slight pressure as market prices in the cash deployment
Deal size is material; investors will assess impact on KKR's liquidity versus long‑term strategic gain.
Market effects
Strengthens the life‑science real‑estate sector and may lift peer REITs focused on biotech campuses.
Boosts investor confidence in San Diego's life‑science hub and related local developments.
Highlights growing private‑equity interest in specialized real‑estate assets worldwide.
Counterpoint
The high valuation could be overpaying for a niche asset, risking lower returns if leasing demand softens.
Key entities
- CompanyKKR & Co. Inc.
Global investment firm making the $475 M investment.
- CompanyAlexandria Real Estate Equities, Inc.
Life‑science REIT receiving the investment.


